EarlySense, the market leader in contact-free continuous monitoring solutions across the care continuum, announced today that new orders for the company’s medical systems grew more than 400% in 2017 compared to 2016. Additionally, EarlySense almost tripled the number of beds being monitored at the end of 2017 compared to the total combined number of beds in the previous 12 years since the company’s founding
EarlySense estimates that its installed systems helped global medical institutions collectively save more than $100 million in 2017 alone. Based on clinical data, these cost savings may be attributed to EarlySense helping clinicians reduce adverse events, such as*:
o Preventing 2,414 falls
o Preventing 10,348 pressure ulcers
o Saving 137,970 patient hospital days
o Preventing 21,615 patient ICU days
o Preventing 2,076 code blues that result from cardiac or respiratory arrest
o Saving 1,765 lives
o Reducing hospital readmissions by over 15%
“More and more facilities, from hospitals to post-acute care sites, are turning to continuous monitoring to support their safety initiatives, meet new regulations, elevate patient care and assist medical teams and staff,” said Avner Halperin, Co-founder and CEO of EarlySense. “At the same time, it is clear that continuous monitoring offers both accuracy and comfort that provides peace of mind for patients and their families. 2017 was an incredible year of growth for EarlySense, and our impact on both clinical and financial outcomes will continue to grow steadily as even more health providers adopt continuous monitoring and embrace the benefits of our technology.”
In addition to the success of its medical device solutions, EarlySense home digital health solutions tracked more than 200,000 nights for home users in 2017. These products, whichleverage EarlySense’s hospital-proven technology, include Live™ for the aging population and the newly launched Percept™ for women who are trying to conceive. EarlySense is the first company ever to bring contact-free clinically-validated technology to the women’s fertility market.
Placed under a bed mattress, EarlySense’s patented sensor utilizes artificial intelligence and big data analysis to accurately monitor heart rate, respiratory rate, motion and sleep. The medical technology is FDA cleared, CE-marked and approved in Canada and South Korea. The home solutions are available for consumer purchase via the EarlySense website and Amazon.
* It is not possible to precisely determine the overall clinical and economic impact of implementing EarlySense systems globally. However, assuming that the outcome achieved in every bed is in line with the results published in the American Journal of Medicine in relation to reduction of adverse events are applicable worldwide, it is generally estimated that by early detection and intervention, clinicians were able to impact patients and hospitals as outlined herein.